Relapse risk after discontinuation of risperidone in Alzheimer's disease.
N. Engl. J. Med., Oct;367(16):1497-507 (2012)
A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease.
Int J Alzheimers Dis., 2012:483469 (2012)
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Int J Geriatr Psychiatry., Sep;26(9):937-43 (2011)
Plasma AÎ² and PET PiB binding are inversely related in mild cognitive impairment.
Neurology., Jul;77(2):125-31 (2011)
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.
Am J Geriatr Psychiatry., Apr;20(4):362-73 (2012)
(99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.
Am J Geriatr Psychiatry., Nov;18(11):959-72 (2010)
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
J Geriatr Psychiatry Neurol., Sep;23(3):185-98 (2010)
Change in cognitive functioning following acute antidepressant treatment in late-life depression.
Am J Geriatr Psychiatry., Oct;17(10):881-8 (2009)
The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease.
Int J Geriatr Psychiatry., Dec;24(12):1335-42 (2009)
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.
Biol. Psychiatry., Nov;64(10):871-9 (2008)
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study.
Int J Geriatr Psychiatry., Jul;23(7):670-6 (2008)
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
Neurology., Mar;68(11):828-36 (2007)
Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.
Arch. Gen. Psychiatry., Aug;63(8):916-24 (2006)
PET network abnormalities and cognitive decline in patients with mild cognitive impairment.
Neuropsychopharmacology., Jun;31(6):1327-34 (2006)
A 10-item smell identification scale related to risk for Alzheimer's disease.
Ann. Neurol., Jul;58(1):155-60 (2005)
Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
Arch. Neurol., Jun;62(6):975-80 (2005)
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
Am J Geriatr Psychiatry., Jan;13(1):59-68 (2005)
Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele).
Am J Geriatr Psychiatry., 12(6):596-605 (2004 Nov-Dec)
Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.
Neuroimage., Sep;23(1):35-45 (2004)
Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients.
J Affect Disord., Mar;78(3):259-67 (2004)